Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2012 (First Quarter of Fiscal Year 2013)
Business Overview: AngioDynamics designs, manufactures, and sells medical devices for vascular access, surgery, peripheral vascular disease, and oncology. Effective June 1, 2012, the company reorganized into a single operating segment. The quarter includes the results of the Navilyst Medical, Inc. acquisition, which closed on May 22, 2012.
Key Financial Metrics
| Metric | Q1 FY2013 (Aug 31, 2012) | Q1 FY2012 (Aug 31, 2011) |
|---|---|---|
| Net Sales | $83.4 million | $54.4 million |
| Gross Profit | $39.5 million (47.3% margin) | $32.1 million (59.1% margin) |
| Operating Income | $0.7 million (0.8% margin) | $2.7 million (5.0% margin) |
| Net (Loss) Income | $(0.7) million | $1.4 million |
| Diluted EPS | $(0.02) | $0.05 |
| Cash & Equivalents | $18.9 million | $50.5 million (end of period) |
| Total Debt | $149.6 million | Not disclosed in summary table |
| Operating Cash Flow | $(5.6) million (used) | $3.0 million (provided) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 53% ($29.0 million) driven primarily by the inclusion of Navilyst products (fluid management, PICCs, ports) and increased NanoKnife sales. This growth was partially offset by the loss of LC Bead sales ($8.0 million in the prior year) following the expiration of the distribution agreement in December 2011.
- Margin Compression: Gross margin declined from 59.1% to 47.3%. This decrease is attributed to the lower-margin product mix from the Navilyst acquisition, a $3.4 million non-cash charge for the amortization of the step-up in basis of acquired inventory, and $0.7 million in costs for the "Quality Call to Action" regulatory program.
- Expense Increases: Operating expenses rose significantly due to the Navilyst acquisition. R&D increased 27%, Sales & Marketing increased 14%, and G&A increased 60%. Amortization of intangibles increased by $1.4 million due to Navilyst assets.
- Profitability: The company reported a net loss of $0.7 million compared to net income of $1.4 million in the prior year. The decline was driven by higher operating expenses, increased interest expense from acquisition debt, and the expiration of the R&D tax credit.
Guidance, Outlook, Risks, and Unusual Items
- Acquisition Integration: The company is integrating Navilyst, which now represents a significant portion of sales. Avista Capital Partners (former Navilyst owners) holds approximately 27% of outstanding shares.
- Regulatory Risks: The FDA issued Form 483 observations regarding the Queensbury and Fremont facilities in early 2012 and a re-inspection in September 2012. Issues included CAPA systems, complaint handling, and training. The company is implementing a "Quality Call to Action" program to address these deficiencies. Failure to resolve these could lead to injunctions or recalls.
- Product Development: The FDA requested additional information regarding the NanoKnife clinical trial for pancreatic cancer in August 2012. The company intends to work with the FDA to address these matters.
- Subsequent Event: On October 8, 2012, the company entered a definitive agreement to acquire Vortex Medical, Inc. for $15 million in cash plus a guaranteed minimum earn-out of $40 million over five years.
- Litigation: Several patent infringement suits are pending (Cirrex Systems, C.R. Bard). The company also obtained a partial judgment of $16.4 million against biolitec, Inc. in September 2012.
- Liquidity: Total debt stands at $149.6 million, primarily from the Navilyst acquisition financing ($150 million term loan). The company believes current cash and operating cash flows are sufficient for the next 12 months.
Investor Verification Checklist
- Regulatory Resolution: Verify the status of FDA Form 483 observations and the timeline for closing out the "Quality Call to Action" program to assess risk of operational disruption.
- Debt Servicing: Review the terms of the $150 million term loan, specifically the quarterly repayment schedule and interest rate exposure (hedged via swap at 3.26% for $100 million).
- Margin Trajectory: Monitor whether gross margins stabilize as the company integrates Navilyst and amortization of the inventory step-up is completed.
- LC Bead Replacement: Assess the success of new products in replacing the $8.0 million quarterly revenue lost from the LC Bead distribution agreement expiration.
- Legal Outcomes: Track the progress of the biolitec litigation to confirm the collectability of the $16.4 million judgment and the status of pending patent suits.